J&J Spotlights AAA Device, Thermocool Extensions During Analyst Meeting
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson is looking to the Nevo sirolimus-eluting stent and entry into fast-growing endovascular device segments, such as the abdominal aortic aneurysm market, to restore growth in its struggling Cordis unit
You may also be interested in...
Cordis Launches Low-Profile Incraft AAA Stent Graft In Europe And Canada
The J&J division has been talking-up Incraft as a potentially major innovation in the treatment abdominal aortic aneurysms for several years.
And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market
The first company to enter the drug-eluting stent market will now be the first to depart.
And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market
The first company to enter the drug-eluting stent market will now be the first to depart.